SEC Form 10-Q filed by Kyverna Therapeutics Inc.
$KYTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $13.00 | Buy | UBS |
| 10/9/2024 | $16.00 | Buy | Rodman & Renshaw |
| 7/3/2024 | $8.00 | Neutral | H.C. Wainwright |
| 3/4/2024 | $40.00 | Overweight | Morgan Stanley |
| 3/4/2024 | $39.00 | Overweight | JP Morgan |
| 3/4/2024 | $44.00 | Overweight | Wells Fargo |
| 3/4/2024 | $48.00 | Outperform | Leerink Partners |
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00
Rodman & Renshaw initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $16.00
H.C. Wainwright initiated coverage of Kyverna Therapeutics with a rating of Neutral and set a new price target of $8.00
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple
Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing patient reach with KYV-102 using whole blood rapid manufacturing Cash runway into 2027 to deliver key milestones EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company fo
SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging impactful partnerships, and Mert's vast experience in leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms will be instrumental as we a
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
S-8 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple
SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging impactful partnerships, and Mert's vast experience in leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms will be instrumental as we a
Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," sai